| Document |
Document Title |
|
JP7475469B2 |
Provided is a vitamin D derivative demonstrating excellent central nervous system migration, or a pharmaceutically acceptable salt or a solvate thereof. Specifically provided is a vitamin D derivative represented by formula (1), or a pha...
|
|
JP2024518143A |
Provided herein are nitrophenyl-acrylamide compounds, their preparation, and their uses. The nitrophenyl-acrylamide compounds described herein have been discovered to be useful and effective therapeutic agents, including in the treatment...
|
|
JP2024054111A |
[Problem] 3-((1R,3R)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azetidin-3-
yl)amino)phenyl)-3-methyl-1, Provided is a method for producing a synthetic intermediate of 3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-2,2-difluoropro
pan-1-ol. [So...
|
|
JP2024516361A |
The present invention relates to novel triazine compounds that contain chemically reactive groups (warheads) and behave as reversible and irreversible covalent inhibitors. A linker has been introduced to target a solvent-exposed cysteine...
|
|
JP2024516194A |
The present invention relates generally to the field of pharmaceutical compounds, and in particular to compounds of formula (I) that act as inhibitors for the PD1/PD-L1 interaction. The invention further relates to a process for the prep...
|
|
JP2024045124A |
The present invention provides an NLRP3 activity regulator. A compound of formula AA or a pharmaceutically acceptable salt thereof is provided. (where m=0, 1, or 2; n=0, 1, or 2; o=1 or 2; p=0, 1, 2, or 3, where A is a 5- to 10-membered ...
|
|
JP2024513606A |
The present invention relates to formula (I) (wherein A, Z, L, R1,R2,R3,R4,R5and R33is defined in claim 1), or a pharmaceutically acceptable salt thereof. Compounds of formula (I) have utility as inhibitors of TEAD. The present compounds...
|
|
JP7449300B2 |
Disclosed are compounds of Formula (I) or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, wherein Q is a 5-membered heterocyclyl or 5-membered heteroaryl having 1 to 4 heteroatoms independently selec...
|
|
JP2024508728A |
The present invention specifically uses compounds as NLRP3 inhibitors, such as compounds represented by the following formula (I), or optical isomers, pharmaceutically acceptable salts, prodrugs, deuterium-substituted derivatives, and hy...
|
|
JP2024508687A |
The present disclosure relates, in part, to chemical modulators of protein phosphatase 2A (PP2A). Compounds of the present disclosure may be used to treat cancer, diabetes, autoimmune diseases, solid organ transplant rejection, graft-ver...
|
|
JP2024508094A |
Formula (I) [wherein, R1,R3,R11,R12,X,Y1,Y2,Y3,Y4and formula (II) are as defined in the description. Medicine.
|
|
JP7436370B2 |
Disclosed are a quaternary ammonium salt compound, a preparation method therefor and a use thereof. Provided is a novel structural compound as shown in formula I, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, ...
|
|
JP2024506612A |
Compounds of formula (I), stereoisomers thereof, deuterated derivatives thereof, or pharmaceutically acceptable salts thereof, intermediates for preparing the compounds, methods for preparing the compounds, which inhibit the activity of ...
|
|
JP2024016311A |
[Assignment] EP2In the prevention and/or treatment of diseases caused by receptor activation, EP2An object of the present invention is to provide a drug whose active ingredient is a compound having antagonistic activity toward a receptor...
|
|
JP2024009891A |
The present invention provides a cyclic amine compound having an amide bond that has a T-type calcium channel inhibitory effect, and a T-type calcium channel inhibitor containing these compounds as an active ingredient. A compound repres...
|
|
JP7416096B2 |
The present document describes compounds, or pharmaceutically acceptable salt thereof, of a core formula (I) where R1 features an amine group, particularly useful in the formulation of lipid particles including nucleic acid therapeutic a...
|
|
JP2024501780A |
The present disclosure relates, in part, to compounds for modulating the activity of aldehyde dehydrogenases, such as ALDH2, or pharmaceutically acceptable salts or solvates thereof, and/or alcohol use disorders, alcohol-induced disorder...
|
|
JP2024003276A |
The present invention provides a novel azetidinone derivative or a salt thereof having excellent herbicidal activity, a herbicide containing the same as an active ingredient, and a production intermediate. [Solution] Specifically, for ex...
|
|
JP7412328B2 |
In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured:or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.
|
|
JP2024501257A |
Compounds and compositions thereof for modulating S1P5 are provided herein. In some embodiments, compounds and compositions are provided for the treatment of neurological diseases. [Selection diagram] None
|
|
JP2024501118A |
Provided herein are compounds that bind to KRAS proteins or variants thereof, pharmaceutical compositions containing the compounds, and methods of using the compounds for the treatment of disease. [Selection diagram] Figure 16
|
|
JP2024500645A |
The present invention provides formula (I): [Formula 1] (wherein the variables are as defined in the claims and specification) and compositions containing these compounds. The invention also relates to the use of said malonamide compound...
|
|
JP7409383B2 |
An object of the present invention is to provide a compound with an improved balance of S1P5 receptor agonist activity with respect to S1P1 receptor, and a form suitable for drug substances of pharmaceuticals. Provided is Compound I havi...
|
|
JP2024001052A |
The present invention provides a compound that is a Bcl-2 inhibitor and a method for producing the same. [Solution] A method for producing a compound of formula (I) or a pharmaceutically acceptable salt thereof, comprising a step of reac...
|
|
JP7406264B2 |
Provided herein are compounds, pharmaceutical compositions comprising the compounds, methods of preparing the compounds, and methods of using the compounds and compositions in treating diseases or disorders in a subject where the subject...
|
|
JP2023554391A |
Kinase inhibitors, pharmaceutical compositions comprising such compounds, and methods of using such compounds or compositions, e.g., proliferative disorders such as cancer or tumors, or in some embodiments, the treatment of kinase inhibi...
|
|
JP7402696B2 |
The present disclosure, among other things, provides technologies for synthesis, including reagents and methods for stereoselective synthesis. In some embodiments, the present disclosure provides compounds useful as chiral auxiliaries. I...
|
|
JP2023552292A |
The present disclosure is directed to chemical compounds and the use of such compounds in the treatment of diseases associated with adrenergic receptors. Compounds according to Formula (I), or optically pure stereoisomers, pharmaceutical...
|
|
JP2023175723A |
To provide compounds with chiral auxiliaries for the synthesis of oligonucleotides with chiral modified internucleotidic linkages, particularly for stereoselective synthesis, reagents derived from the compound, and synthesis methods usin...
|
|
JP2023550479A |
The present disclosure relates to arylamidines of formula (I) and their use as fungicides. [Formula 1]
|
|
JP2023548169A |
Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases, disorders, and diseases. [Selection diagram] None
|
|
JP2023547770A |
The present disclosure provides compounds, pharmaceutical compositions comprising such compounds, and methods or treatments for the treatment of inflammatory diseases and certain neurological disorders associated with inflammatory signal...
|
|
JP2023546899A |
Formula (I): [Formula 1] [In the formula, R1 and R2 represent a hydrogen atom or a deuterium atom; R3 represents a hydrogen atom, -COOH group, or -OH group; R3' and R3'' represent a hydrogen atom, a methyl group, a methoxy group, Represe...
|
|
JP2023546100A |
Glutamine analogs, compositions containing glutamine analogs and uses thereof.
|
|
JP2023545552A |
The present invention provides formula (I): [Formula 1] [In the formula, R1 and R2 represent a hydrogen atom or a deuterium atom; R3 represents a hydrogen atom, -COOH group or -OH group; R3' and R3'' represent hydrogen, methyl, methoxy, ...
|
|
JP7365358B2 |
Disclosed are small molecule antagonists of α4β7 integrin, and methods of using them to treat a number of specific diseases or conditions.
|
|
JP2023542512A |
Compounds of formula (I) and their pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers, pharmaceutical compositions containing them, methods of making them, and pain relief , mental disorders, neurological ...
|
|
JP7355741B2 |
Compounds of Formula (I) are provided herein. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions, including conditions characterized by excessive cellular...
|
|
JP2023540661A |
The present invention provides compounds of formula (I) as CCR8 inhibitors, which can be used to treat or prevent cancer using CCR8 inhibitors that target tumor-specific regulatory T cells. can be done. Formula (I): [Selection diagram] None
|
|
JP2023538842A |
[Solution] The present invention contains monomeric diphenylmethane diisocyanate (MDI) as component (q1), and an amide with a molecular weight of less than 200 g/mol as component (q2), the total of components (q1) and (q2) being 100% by ...
|
|
JP2023538614A |
The present invention relates to processes for preparing itacitinib, or salts thereof, and related synthetic intermediates related thereto.
|
|
JP7339677B2 |
Disclosed in the present invention were a fluorosulfonyl-containing compound, an intermediate thereof, a preparation method therefor and use thereof. The fluorosulfonyl-containing compound disclosed in the present invention comprises a c...
|
|
JP2023538060A |
The present invention relates to compounds of formula (I), pharmaceutical compositions containing them, and uses thereof It is. Said compounds treat, prevent or ameliorate diseases or disorders such as cancer. used to do [Chemical 100] [...
|
|
JP2023536207A |
This application describes the preparation of 4-[3-{3-[(cyclopropylamino)methyl]azetidine-1-carbonyl)-4-fl
uorobenzyl]phthalazin-1(2H)-one or a pharmaceutically acceptable sail thereof intermediates in its preparation; methods of prepari...
|
|
JP7332469B2 |
The invention provides sulfoxyalkyl organonitro and related compounds, compositions containing such compounds, and methods for using such compounds and compositions to treat medical disorders, such as a neurodegenerative disorder, autoim...
|
|
JP2023535957A |
Disclosed are compounds of Formula 1, stereoisomers, N-oxides, and salts thereof, [Chemical 1] where G is CONR5R.6or [Chemical 2] is selected from R.1~R18, Rfand G are as defined in this disclosure. Also disclosed is a composition contai...
|
|
JP2023535323A |
The present invention uses the formula (I) [wherein R1, R2, R3, R4and m are as defined herein] or a pharmaceutically acceptable salt or solvate thereof. The invention further relates to pharmaceutical compositions containing cyclic cyano...
|
|
JP2023113615A |
To provide a novel compound that is useful in the treatment of diseases associated with TEAD transcription factor activity.The problem is solved by a compound of formula (I), or a pharmaceutically acceptable salt thereof. [L1 is absent o...
|
|
JP2023534528A |
The present disclosure relates to sulfur-containing isoindoline derivatives, methods for their preparation and their pharmaceutical applications. Specifically, the present disclosure provides a sulfur-containing isoindoline derivative re...
|
|
JP2023533986A |
In particular, novel compounds for inhibiting HDAC or HDAC activity, and more particularly for promoting renal recovery after acute kidney injury (AKI), preferably by inhibiting HDAC, and compositions comprising the same, the manufacture...
|
